MetrioPharm Press Releases
-
MetrioPharm AG has submitted the phase I investigational new drug application for MP1032
MetrioPharm AG has submitted the phase I investigational new drug application for its lead compound MP1032 to BfArM (German Federal Institute for Drugs and Medical Devices).
-
MetrioPharm AG attracts high profile pharma executive
In November 2014, John J. Alam, M.D. joined MetrioPharm AG as Senior Medical Advisor and Non-Executive Board Member.
-
MetrioPharm AG: Phase I – the next step
Since MetrioPharm AG was able to finalize the regulatory pharmacology and toxicology studies in the past months, all requirements for clinical studies are now fulfilled.
-
MetrioPharm AG: 9th International Congress on Autoimmunity (Nice)
On March 26. – 30. 2014 over 2000 scientists from around the world met in Nice for the 9th International Congress on Autoimmunity.
-
MetrioPharm Milestones – on the route to a new drug
The most important outcome was MP1032's superior safety profile as confirmed by the results from the various regulatory pharmacology and toxicology studies conducted throughout the past year.